Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2018-08-17 Board/Management Inform…
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated August 17, 2018. The key content is the resignation of a Chief Financial Officer and General Counsel, and the appointment of new principal financial and accounting officers. This is an announcement of changes in senior management positions. There are no financial statements or detailed financial data presented, so it is not an Annual Report, Interim Report, or Earnings Release. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's board of directors or senior management.
2018-08-17 English
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report Q2 2018
2018-08-09 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 8, 2018. It announces the issuance of a press release reporting financial results for the second quarter ended June 30, 2018. The document itself does not contain detailed financial statements or substantive financial data but refers to the press release attached as an exhibit. The length of the document is 3651 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, such a document that announces the release of financial results without including the full report should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR).
2018-08-09 English
FORM 10-Q/A
Interim / Quarterly Report Q1 2018
2018-08-09 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated July 27, 2018, by Cidara Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically a Second Amendment to a Loan and Security Agreement. The content focuses on financing terms such as maturity date extension, interest-only period extension, and interest rate amendments. There are no financial statements or comprehensive financial performance data included. The document is a regulatory announcement about a financing update rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3605 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2018-07-31 English
Regulatory Filings 2018
Regulatory Filings
2018-07-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.